Corcept Therapeutics Incorporated
CORT
Rank in Stocks
#1761
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Share Price
$112.72
Market Cap
$12.18B
Change (1 day)
2.32%
Change (1 year)
43.25%
Country
US
Trade Corcept Therapeutics Incorporated (CORT)
Category
Healthcare
P/E ratio for Corcept Therapeutics Incorporated (CORT)
P/E ratio as of October 2026 TTM: 223.52
According to Corcept Therapeutics Incorporated latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 223.52. At the end of 2023 the company had a P/E ratio of 31.69.
P/E ratio history for Corcept Therapeutics Incorporated from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 223.52 | 500.37% |
| 2024 | 37.23 | 17.47% |
| 2023 | 31.69 | 48.19% |
| 2022 | 21.39 | 5.07% |
| 2021 | 20.35 | -28.54% |
| 2020 | 28.48 | 93.86% |
| 2019 | 14.69 | -34.02% |
| 2018 | 22.27 | 40.23% |
| 2017 | 15.88 | -83.90% |
| 2016 | 98.61 | -218.81% |
| 2015 | -83.00 | 759.85% |
| 2014 | -9.65 | 38.61% |
| 2013 | -6.96 | 99.20% |
| 2012 | -3.50 | -60.30% |
| 2011 | -8.81 | -13.31% |
| 2010 | -10.16 | 40.51% |
| 2009 | -7.23 | 204.34% |
| 2008 | -2.38 | -74.02% |
| 2007 | -9.15 | 709.65% |
| 2006 | -1.13 | -72.50% |
| 2005 | -4.11 | -44.64% |
| 2004 | -7.42 | -31.19% |
| 2003 | -10.78 | 142.75% |
| 2002 | -4.44 | -49.65% |
| 2001 | -8.82 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 24.47 | -89.05% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 33.58 | -84.98% |
HK
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.